Dotarem® is a macrocyclic-structured gadolinium-based MRI contrast agent. Launched in France in 1989, Dotarem® is currently marketed in more than 70 countries.
Dotarem® combines optimal performance and excellent safety. In a large surveillance study with more 84,000 examinations, Dotarem demonstrated optimal efficacy in clinical practice.1 Dotarem has also proved its safety profile and is classified under the low risk group by Guidelines from main Health Authorities/Scientific societies: EMA, ESUR, FDA, American College of Radiology, Danish Health and Medicine Authority.
Dotarem® 0.5 mmol/mL, solution for injection
- Glass vials: 5 mL, 10 mL, 15 mL, 20 mL, 60 mL or 100 mL
Glass prefilled syringes: 10 mL, 15 mL or 20 mL
(Not all pack sizes may be marketed – Please refer to your local SmPC)
1 Maurer M et al. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol. 2012 May;81(5):885-90.